Clinical Trial Details

If you are a patient or a caregiver and would like to learn more our cancer clinical trials
call toll-free 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials) or
email cancerclinicaltrials@bsd.uchicago.edu.

The purpose of this randomized, open-label study is to evaluate the safety and efficacy of
denintuzumab mafodotin plus RICE (rituximab, ifosfamide, carboplatin, and etoposide) when
compared to RICE alone in the treatment of patients with relapsed or refractory diffuse
large B-cell lymphoma (DLBCL) or Grade 3b follicular lymphoma. Eligible patients must also
be candidates for autologous stem cell transplant. Patients will be randomly assigned in a
1:1 ratio to receive 3 cycles of study treatment with either denintuzumab mafodotin + RICE
or RICE alone. The study will assess whether there is a difference between the 2 groups in
the side effects that are reported and the number of patients who achieve complete remission
at the end of their study treatment.